Use of multi-specific, non-covalent complexes for targeted delivery of therapeutics
AssigneeImmunomedics, Inc.
InventorsGary L. Griffiths, Serengulam V. Govindan, Hans J. Hansen
Life of this patent
Estimating the term…
Abstract
The invention relates to a method for treating target cells, tissues or pathogens in a subject, comprising administering a non-covalently bound complex which comprises a multispecific targeting protein and a hapten-enzyme covalent conjugate. The invention further relates to kits comprising the non-covalently bound complex or the components to prepare the complex.
Claims41
A method for treating target cells, tissues or pathogens in a subject comprising administering in sequence:
- a) a therapeutically effective amount of a non-covalently bound complex to said subject thereby forming a target-tissue-localized complex;
- wherein said non-covalently bound complex comprises a multispecific targeting protein comprising at least one target-binding site and one hapten-binding site, and a hapten-enzyme covalent conjugate;
- wherein said at least one target-binding site is capable of binding to at least one complementary binding moiety on the target cells, tissues or pathogens or on a molecule produced by or associated with said target cells, tissues or pathogens;
- and
- wherein said hapten-binding site is non-covalently bound to the hapten-enzyme covalent conjugate;
- b) optionally, a clearing agent;
- and
- c) a chemotherapeutic drug or prodrug, capable of being converted to a more active drug by the target-tissue-localized complex.
A kit comprising, in suitable containers:
- a) a multispecific targeting protein, comprising at least one target-binding site and a hapten-binding site, pre-mixed with a hapten-enzyme conjugate;
- and
- b) a chemotherapeutic prodrug,
- wherein a) and/or b) optionally further comprise a pharmaceutically acceptable carrier.
A kit comprising, in separate, suitable containers:
- a) a multispecific targeting protein, comprising at least one target-binding site and a hapten-binding site;
- b) a hapten-enzyme conjugate;
- and
- c) a chemotherapeutic prodrug;
- wherein said multispecific targeting protein, comprising at least one target-binding site and a hapten-binding site and said hapten-enzyme conjugate are mixed immediately prior to use,
- wherein a), b) and/or c) optionally further comprise a pharmaceutically acceptable carrier.
A method of making a stable non-covalently bound complex that is capable of localizing to a target cell, tissue, or pathogen comprising admixing a multispecific targeting protein comprising at least one target-binding site and a hapten-binding site, and a hapten-enzyme covalent conjugate;
- wherein said at least one target-binding site is capable of binding to at least one complementary binding moiety on said target cells, tissues or pathogens or on a molecule produced by or associated with said target cells, tissues or pathogens;
- and
- wherein said hapten-binding site is capable of stably and non-covalently binding said hapten-enzyme conjugate;
- thereby making a stable non-covalently bound complex.
A method of treating a subject, comprising administering a therapeutically effective amount of a non-covalently bound complex, said non-covalently bound complex resulting from the pre-mixing of said multi-specific targeting protein and a hapten-enzyme conjugate, prior to administration to said subject.
Dependencies are inferred from the claim text.